Navigation Links
Plato BioPharma, Inc. Sponsors Novel Disease Model Award
Date:4/1/2011

WESTMINSTER, Colo., April 1, 2011 /PRNewswire/ -- Plato BioPharma, Inc. ("PBI") announced today that the company has committed to sponsor The American Physiological Society's (APS) Novel Disease Model Awards for 2011 through 2013.  Each year, the APS's Physiologists in Industry Committee selects a Predoctoral and Postdoctoral fellow at the Experimental Biology conference as award recipients based on competitive abstract submissions.

"PBI embraces sponsorship of these awards to recognize outstanding trainees participating in, and driving toward approaches to study physiological mechanisms and consequences of diseases in integrative and mechanistically novel systems," said Craig F. Plato, Ph.D., CEO and founder of PBI.  "Additionally, as PBI is a preclinical contract research organization emphasizing physiological readouts in its assessment of disease models, as well as novel and integrative approaches to evaluate potential new therapeutic approaches to modify pathophysiological derangements, the Novel Disease Model Awards are squarely aligned with our scientific and business focus.  Thus, PBI truly appreciates the impact of recognizing young and talented investigators making contributions to the study and development of preclinical models of disease that may yield new avenues in the process of drug discovery."

This year's awards will be announced at the Experimental Biology conference, which is scheduled for April 9-13, 2011 in Washington, D.C.  Craig F. Platoof, PBI, and Martin Frank, Ph.D., Executive Director of The APS, will present the Novel Disease Model awards to the recipients at the APS Business Meeting.

Founded in 2009, Plato BioPharma, Inc. is a leading preclinical contract research organization (CRO).  The company offers expert drug discovery and development capabilities in cardiovascular, renal, pulmonary, and hepatic disease therapeutic areas.  PBI provides an integrated research platform from the in-life phase through clinical chemistry, biomarker and histological analyses.  The company specializes in custom study design and execution engagements ranging from pharmacokinetics through disease model and proof-of-concept evaluation.  PBI is headquartered in Westminster, Colorado.

CONTACT: Bob Leahy, +1-303-506-6960, for Plato BioPharma, Inc.


'/>"/>
SOURCE Plato BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
2. New PLATO Sub-Analysis of CABG Patients Presented at ACC
3. Plato BioPharma, Inc Appoints New Board Member
4. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
5. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
6. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
7. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
8. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
9. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
10. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase of ... and an increase of 1.2% on an adjusted pro forma, ... quarter were $0.52 reported, a decrease of 47.5% from the ... over the prior year period , The Company increases ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... April 27, 2016 ... Forums in Zürich gab Strekin AG den ... STR001 zur Erhaltung des Resthörvermögens von Patienten, ... Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden ... STR001 wird während der Operation direkt ins ...
Breaking Medicine Technology:
(Date:5/2/2016)... , ... May 02, 2016 , ... Pregnancy Awareness Month ... trying to conceive. , “If you are ready to have a baby, ... “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy Organizer, written ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... division of Permobil, recently completed two groundbreaking studies that determined that the adjustability ... – are critical in the prevention of pressure injuries, which are now referred ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... Model Could Transform the Pharma Landscape .” CMS recently proposed a test of alternate ... provider-administered drugs while preserving care provided to beneficiaries. The webinar will review the details ...
(Date:5/2/2016)... ... , ... The Evolve Paddle Board Company- which specializes in the production and ... their partnership with Yoloha Yoga- producers of high quality cork yoga mats. Together they ... seen a dramatic rise in popularity throughout the last few years. The makers of ...
(Date:5/2/2016)... ... May 02, 2016 , ... Summit BHC (Summit), a leading ... Twin Lakes Recovery Center. Located east of Atlanta in Monroe, Georgia, the ... residential facility is set on 34 acres of beautiful, secluded property that will ...
Breaking Medicine News(10 mins):